➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Colorcon
AstraZeneca
Dow
Mallinckrodt

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ALLOPURINOL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Allopurinol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004314 Phase II Pilot Study of Aminoimidazole Carboxamide Riboside (AICAR), a Precursor of Purine Synthesis, for Lesch-Nyhan Disease Completed University of California, San Diego Phase 2 1996-02-01 OBJECTIVES: I. Determine the effects of aminoimidazole carboxamide riboside (AICAR) on hematologic manifestations of Lesch-Nyhan disease. II. Assess the behavioral and neurological benefits of AICAR in patients with Lesch-Nyhan disease. III. Examine the effect of AICAR on purine production.
NCT00004314 Phase II Pilot Study of Aminoimidazole Carboxamide Riboside (AICAR), a Precursor of Purine Synthesis, for Lesch-Nyhan Disease Completed National Center for Research Resources (NCRR) Phase 2 1996-02-01 OBJECTIVES: I. Determine the effects of aminoimidazole carboxamide riboside (AICAR) on hematologic manifestations of Lesch-Nyhan disease. II. Assess the behavioral and neurological benefits of AICAR in patients with Lesch-Nyhan disease. III. Examine the effect of AICAR on purine production.
NCT00004755 Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil Completed Harvard School of Public Health Phase 2 1995-09-01 OBJECTIVE: Compare the efficacy and side effects of allopurinol versus glucantime versus allopurinol/glucantime in patients in Brazil with cutaneous leishmaniasis.
NCT00004755 Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1995-09-01 OBJECTIVE: Compare the efficacy and side effects of allopurinol versus glucantime versus allopurinol/glucantime in patients in Brazil with cutaneous leishmaniasis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Allopurinol

Condition Name

Condition Name for Allopurinol
Intervention Trials
Gout 37
Hyperuricemia 17
Leukemia 16
Chronic Lymphocytic Leukemia 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Allopurinol
Intervention Trials
Leukemia 30
Gout 28
Leukemia, Lymphoid 27
Hyperuricemia 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Allopurinol

Trials by Country

Trials by Country for Allopurinol
Location Trials
United States 637
Canada 47
Australia 23
Spain 17
Germany 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Allopurinol
Location Trials
Texas 56
California 31
Florida 24
North Carolina 23
New York 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Allopurinol

Clinical Trial Phase

Clinical Trial Phase for Allopurinol
Clinical Trial Phase Trials
Phase 4 39
Phase 3 38
Phase 2/Phase 3 6
[disabled in preview] 60
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Allopurinol
Clinical Trial Phase Trials
Completed 84
Recruiting 28
Not yet recruiting 27
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Allopurinol

Sponsor Name

Sponsor Name for Allopurinol
Sponsor Trials
M.D. Anderson Cancer Center 22
Ardea Biosciences, Inc. 14
AstraZeneca 9
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Allopurinol
Sponsor Trials
Other 223
Industry 84
NIH 23
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Merck
Baxter
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.